<%If Len(Trim(strHeaderImage)) <> 0 then%> " border="0" class="TitleHeaderImg" alt="" /><%End If%> If instr(strURL, Token & "pageguid=")>0 Then If instr(strParentPages, Mid(strURL, instrrev(strURL, Token & "pageguid="), 42))>0 Then isActive=True Else isActive=False End If Else isActive=False End If End Function %> <% If isActive("/patients/patients.html") Then strLinkClass = "class = ""MainNavActive""" Else strLinkClass = "" End If %> > Patients <% If isActive("/medpro/medical...
Amgen - Media - Feature - Amgen Promotes Breakaway from Cancer™ Initiative About Amgen Science Corporate Philanthropy Site Map Search Privacy & Terms Contact Us Patients Medical Professionals Partners Investors Careers Media print mail Home Media Featured Content Amgen’s Statement on the Safety of Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa) Overview Fact Sheets Featured Content Press Releases Awards & Recognition...
Amgen - Medical Professionals - Products - PRCA Update EPOGEN/Procrit and Eprex share the same International Non-proprietary Name (Epoetin alfa), however, Eprex is not equivalent to EPOGEN/Procrit.- The products are manufactured by different companies in different facilities, using different methods and formulations.- Epoetin beta is a different product than Epoetin alfa, manufactured by...
Amgen - Patients - Products - PRCA Update EPOGEN/Procrit and Eprex share the same International Non-proprietary Name (Epoetin alfa), however, Eprex is not equivalent to EPOGEN/Procrit.- The products are manufactured by different companies in different facilities, using different methods and formulations.- Epoetin beta is a different product than Epoetin alfa, manufactured by...
Amgen - Media - Featured Content About Amgen Science Corporate Philanthropy Site Map Search Privacy & Terms Contact Us Patients Medical Professionals Partners Investors Careers Media print mail Home Media Featured Content Overview Fact Sheets Featured Content Press Releases Awards & Recognition Media Contacts In the News Date Title 2/25/2008 Amgen Foundation Expands Giving to Europe - The Amgen Foundation is proud...
Amgen - Medical Professionals - Products - PRCA Update EPOGEN/Procrit and Eprex share the same International Non-proprietary Name (Epoetin alfa), however, Eprex is not equivalent to EPOGEN/Procrit.- The products are manufactured by different companies in different facilities, using different methods and formulations.- Epoetin beta is a different product than Epoetin alfa, manufactured by...
Amgen - Patients - Products - PRCA Update EPOGEN/Procrit and Eprex share the same International Non-proprietary Name (Epoetin alfa), however, Eprex is not equivalent to EPOGEN/Procrit.- The products are manufactured by different companies in different facilities, using different methods and formulations.- Epoetin beta is a different product than Epoetin alfa, manufactured by...
Amgen EPOGEN/Procrit and Eprex share the same International Non-proprietary Name (Epoetin alfa), however, Eprex is not equivalent to EPOGEN/Procrit.- The products are manufactured by different companies in different facilities, using different methods and formulations.- Epoetin beta is a different product than Epoetin alfa, manufactured by...
Amgen Amgen - Patients - Products - PRCA Update EPOGEN/Procrit and Eprex share the same International Non-proprietary Name (Epoetin alfa), however, Eprex is not equivalent to EPOGEN/Procrit.- The products are manufactured by different companies in different facilities, using different methods and formulations.- Epoetin beta is a different product than Epoetin alfa, manufactured by...
BIOPHARMA EPO rDNA Amgen SAMPLE MONOGRAPH: EPO, rDNA/Amgen Epoetin alfa - Epogen; Procrit; Erythropoietin, recombinant Status: approved; marketed Organizations involved: Amgen, Inc.Epoetin alfa at 40,000 Units/mL, alone with 2.5 mg Albumin (Human), 1.2 mg sodium phosphate monobasic monohydrate, 1.8 mg sodium...
BioPortfolio Limited AS Insights Opportunity and Valuation Reports Many new and emerging dedicated biogenerics companies have launched their products in selected niche markets and many licensing opportunities for fully developed generics versions of epoetin alfa are available for the taking.
BioPortfolio Client Press Releases Site Map Society for Biomolecular Screening new product Fast Track Regulatory Approval for TheraCIM h-R3, a new drug for the treatment of Epidermal Growth Factor Receptor (EGF-R) BioPortfolio BioNews (News & Press Releases) PerkinElmer Life Sciences and NextGen Sciences Partner in Fast-track Development of the First Fully Automated System for Processing Protein Microarrays RiboTargets Listed...
BioPortfolio Limited Companies & Products 4.1 Overview 4.1.1 Historical Perspective 4.1.2 Dosage & Formulations 4.1.2.1 Recombinant Erythropoietin 4.1.2.2 Aranesp (darbepoetin alfa) 4.1.3 Decision Making & Dispensing Dynamics 4.1.4 Present Pricing Strategy 4.1.5 Reimbursement Status 4.1.6 Key Patents Expiry Dates 4.1.6.1 Epoetin Alfa Key Patents Expiry Dates 4.1.6.2 Darbepoetin Alfa ...
R & D Systems - Cytokine Bulletin Advanced Search Printer-friendly version Subscribe to the Cytokine Bulletin E-mail Erythropoietin: Good or Bad for Cancer?
http://www.adis.com/files/newsletters/REA/Rxcov985.pdf 20 Haloperidol/ levomepromazine: perceptual disorder [ ] 10 Pharmacovigilance & Regulatory News Imatinib: fatal hepatic necrosis [S] 10 Epoetin alfa [Eprex] prescribing information revised in Canada 2 Immunoglobulins: thrombocytopenia [ S] 11 Methadone: labelling change in Switzerland 2 Infliximab: polymyositis [S] 11 Sevoflurane and desiccated CO2 absorbent may...
http://www.adis.com/files/newsletters/INP/Icov1421.pdf 10 MUSCULOSKELETAL IFN (low- dose): no benefit in high- risk melanoma 18 Ibandronic acid: monthly vs daily in postmenopausal women 6 Imatinib for residual disease in paediatric Ph+ CML 10 Immunostimulatory DNA in cancer immunotherapy 3 NEPHROLOGY Interferon- effective in malignant melanomas 14 Epoetin beta: paediatric weight- based dosing unnecessary 20 MPI 176716: antitumour...
Janssen Pharmaceutica For more detailed information please visit the websites of our marketing- & sales companies via www.janssen-cilag.com The medicines for human health discovered and developed by our research centres include: - Trademark Generic name Therapeutic area Cilest™ ethinyloestradiol-+ norgestimate oral contraceptive Daktarin™ miconazole antimycotic Durogesic™ fentanyl patch...
Janssen Pharmaceutica true : false; function fDoSearch(){ var tmpString = document.frmSearch.target.value; if (tmpString.length < 1){ alert('Search criteria should be at least 2 characters or digits long.'); } else{ fSubmitForm(); } } function fSubmitForm(){ document.frmSearch.submit(); } function fCheckEnter(){ var code = 0; if (NS4) code = event.which; else code = event.keyCode; if (code==13) fDoSearch(...
Janssen Pharmaceutica |- Nederlands -| -English-| nextAd() NS4 = (document.layers)
Prescription Drug User Fee Act - User Fee Billable Therapeutic Products: Approved Under Section 351 of the PHS Act u/vial MedImmune, Inc License 1252 Synagis Palivizumab 103770/0 6/19/1998 50 mg/vial 100 mg/vial Merck & Co., Inc License 0002 Elspar Asparaginase 101063/0 1/10/1978 10,000 IU/vial Novartis Pharmaceuticals Corp License 1244 Simulect Basiliximab 103764/0 5/12/1998 10 mg/vial 20 mg/vial OMJ Pharmaceuticals, Inc License 1196 Regranex Becaplermin 103691/0 12/16/1997 100 mcg Ortho...
Amgen s 2002 10K filing with the Securities and Exchange Commission page 11
author: Durk Hubel
subject: Amgen s 2002 10K filing with the Securities and Exchange Commission
duplicates:http://www.immunex.com/pdf/0010k.pdf http://www.immunex.com/pdf/0010k.pdf
Amgen s 2002 10K filing with the Securities and Exchange Commission The Company markets human therapeutic products including, EPOGEN ® (Epoetin alfa), Aranesp ® (darbepoetin alfa), NEUPOGEN ® (Filgrastim), Neulasta ’ (pegfilgrastim), and Kineret ® (anakinra)Epoetin alfa) EPOGEN ® (proper name„ Epoetin alfa) is Amgen's registered trademark for its...
author: Durk Hubel
subject: Amgen s 2002 10K filing with the Securities and Exchange Commission
CBER Transfer of Therapeutic Products to CDER Alteplase Activase Genentech, Inc Anakinra Kineret Amgen, Inc Anistreplase Eminase Wulfing Pharma GmbH Arcitumomab CEA-Scan Immunomedics, Inc Asparaginase Elspar Merck & Co., Inc Basiliximab Simulect Novartis Pharmaceuticals Corp Becaplermin Regranex OMJ Pharmaceuticals, Inc Becaplermin Concentrate - Chiron Corp Botulinum Toxin Type A BOTOX BOTOX COSMETIC Allergan, Inc Botulinum...
author: FDA / CBER
http://www.neose.com/pdf/Pages_10-14.pdf Glycosylation: a critical issue in protein development and manufacturing R ecombinant proteins and monoclonal antibodies offer great promise as therapeutics for a myriad of diseasesEPREX (epoetin alfa, Amgen Inc/ Ortho Biotech), are...
http://www.neose.com/pdf/Pages_10-14.pdf page 1
